Lu ZR - Search Results

1

Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.

Vaidya A, Ayat N, Buford M, Wang H, Shankardass A, Zhao Y, Gilmore H, Wang Z, Lu ZR. Vaidya A, et al. Among authors: lu zr. Theranostics. 2020 Sep 8;10(24):11127-11143. doi: 10.7150/thno.47448. eCollection 2020. Theranostics. 2020. PMID: 33042274 Free PMC article.

2

Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging.

Tan M, Wu X, Jeong EK, Chen Q, Lu ZR. Tan M, et al. Among authors: lu zr. Biomacromolecules. 2010 Mar 8;11(3):754-61. doi: 10.1021/bm901352v. Biomacromolecules. 2010. PMID: 20131758 Free PMC article.

3

Integrin Targeted MR Imaging.

Tan M, Lu ZR. Tan M, et al. Among authors: lu zr. Theranostics. 2011 Jan 19;1:83-101. doi: 10.7150/thno/v01p0083. Theranostics. 2011. PMID: 21547154 Free PMC article.

4

MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Tan M, Burden-Gulley SM, Li W, Wu X, Lindner D, Brady-Kalnay SM, Gulani V, Lu ZR. Tan M, et al. Among authors: lu zr. Pharm Res. 2012 Apr;29(4):953-60. doi: 10.1007/s11095-011-0635-y. Epub 2011 Dec 3. Pharm Res. 2012. PMID: 22139536 Free PMC article.

5

Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer.

Wu X, Burden-Gulley SM, Yu GP, Tan M, Lindner D, Brady-Kalnay SM, Lu ZR. Wu X, et al. Among authors: lu zr. Bioconjug Chem. 2012 Aug 15;23(8):1548-56. doi: 10.1021/bc300009t. Epub 2012 Aug 1. Bioconjug Chem. 2012. PMID: 22812444 Free PMC article.

6

Gadolinium-based contrast agents for magnetic resonance cancer imaging.

Zhou Z, Lu ZR. Zhou Z, et al. Among authors: lu zr. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Jan-Feb;5(1):1-18. doi: 10.1002/wnan.1198. Epub 2012 Oct 9. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013. PMID: 23047730 Free PMC article. Review.

7

MR molecular imaging of prostate cancer with a small molecular CLT1 peptide targeted contrast agent.

Wu X, Lindner D, Yu GP, Brady-Kalnay S, Lu ZR. Wu X, et al. Among authors: lu zr. J Vis Exp. 2013 Sep 3;(79):50565. doi: 10.3791/50565. J Vis Exp. 2013. PMID: 24056726 Free PMC article.

8

Multifunctional PEG retinylamine conjugate provides prolonged protection against retinal degeneration in mice.

Yu G, Wu X, Ayat N, Maeda A, Gao SQ, Golczak M, Palczewski K, Lu ZR. Yu G, et al. Among authors: lu zr. Biomacromolecules. 2014 Dec 8;15(12):4570-8. doi: 10.1021/bm501352s. Epub 2014 Nov 20. Biomacromolecules. 2014. PMID: 25390360 Free PMC article.

9

EDB Fibronectin Specific Peptide for Prostate Cancer Targeting.

Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, Chen Y, Zhu H, Magi-Galluzzi C, Lu ZR. Han Z, et al. Among authors: lu zr. Bioconjug Chem. 2015 May 20;26(5):830-8. doi: 10.1021/acs.bioconjchem.5b00178. Epub 2015 Apr 15. Bioconjug Chem. 2015. PMID: 25848940

10

A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.

Ye Z, Zhou Z, Ayat N, Wu X, Jin E, Shi X, Lu ZR. Ye Z, et al. Among authors: lu zr. Contrast Media Mol Imaging. 2016 Jan-Feb;11(1):32-40. doi: 10.1002/cmmi.1655. Epub 2015 Jul 27. Contrast Media Mol Imaging. 2016. PMID: 26218648 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page